TY - JOUR
T1 - Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China
T2 - A nation-wide multicenter study
AU - Guo, Fengzhu
AU - Yi, Zongbi
AU - Wang, Wenna
AU - Han, Yiqun
AU - Yu, Pei
AU - Zhang, Su
AU - Ouyang, Quchang
AU - Yan, Min
AU - Wang, Xiaojia
AU - Hu, Xichun
AU - Jiang, Zefei
AU - Huang, Tao
AU - Tong, Zhongsheng
AU - Wang, Shusen
AU - Yin, Yongmei
AU - Li, Hui
AU - Yang, Runxiang
AU - Yang, Huawei
AU - Teng, Yuee
AU - Sun, Tao
AU - Cai, Li
AU - Li, Hongyuan
AU - Chen, Xi
AU - He, Jianjun
AU - Liu, Xinlan
AU - Yang, Shune
AU - Fan, Jinhu
AU - Qiao, Youlin
AU - Wang, Jiayu
AU - Xu, Binghe
N1 - Funding Information:
This study was supported by the Investigator‐initiated program of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CH‐BC‐045).
Publisher Copyright:
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Anthracycline-based chemotherapy (ABC) is one of the standard therapies against breast cancer. However, few guidelines are currently available to optimize the use of ABC. Therefore, the present analysis aimed at determining the profile and treatment patterns of ABC and the association of clinicopathological characteristics with ABC selection. Methods: We retrospectively analyzed the data of a nation-wide multicenter epidemiological study, which collected the medical records of breast cancer patients receiving chemotherapy in different settings from seven geographic regions in China (NCT03047889). Results: In total, 3393 patients were included, with 2917 treated with ABC. Among them, 553 (89.8%), 2165 (81.7%), and 814 (25.7%) were subjected to ABC as neoadjuvant, adjuvant, and advanced chemotherapy, respectively. The most frequently used regimens were anthracycline-taxane-based combinations for neo- and adjuvant chemotherapy, along with taxanes and oral fluorouracils for the palliative stages. In the overall cohort, patients aged < 40 or 40-65 (p < 0.001), in premenopause (p < 0.001), without comorbidities (p = 0.016), with invasive ductal carcinoma (p= 0.001), high lymph node involvement (p < 0.001), in the pTNM stage II, III, or IV versus stage I (p < 0.001), subjected to mastectomy (p < 0.001) or subjected to sentinel lymph node biopsy combined with axillary lymph node dissection (p = 0.044), or with a decreased disease-free survival (p < 0.001) were more likely to be recommended to ABC. Conclusion: Taken together, ABC remained the mainstay of breast cancer treatment, especially in neo and adjuvant therapy. ABC was mainly used as a combination therapy, and the correlation between influencing factors and ABC choice varied during different settings, indicating the preference and different perspectives of medication considered by medical oncologists regarding the use ABC in China.
AB - Background: Anthracycline-based chemotherapy (ABC) is one of the standard therapies against breast cancer. However, few guidelines are currently available to optimize the use of ABC. Therefore, the present analysis aimed at determining the profile and treatment patterns of ABC and the association of clinicopathological characteristics with ABC selection. Methods: We retrospectively analyzed the data of a nation-wide multicenter epidemiological study, which collected the medical records of breast cancer patients receiving chemotherapy in different settings from seven geographic regions in China (NCT03047889). Results: In total, 3393 patients were included, with 2917 treated with ABC. Among them, 553 (89.8%), 2165 (81.7%), and 814 (25.7%) were subjected to ABC as neoadjuvant, adjuvant, and advanced chemotherapy, respectively. The most frequently used regimens were anthracycline-taxane-based combinations for neo- and adjuvant chemotherapy, along with taxanes and oral fluorouracils for the palliative stages. In the overall cohort, patients aged < 40 or 40-65 (p < 0.001), in premenopause (p < 0.001), without comorbidities (p = 0.016), with invasive ductal carcinoma (p= 0.001), high lymph node involvement (p < 0.001), in the pTNM stage II, III, or IV versus stage I (p < 0.001), subjected to mastectomy (p < 0.001) or subjected to sentinel lymph node biopsy combined with axillary lymph node dissection (p = 0.044), or with a decreased disease-free survival (p < 0.001) were more likely to be recommended to ABC. Conclusion: Taken together, ABC remained the mainstay of breast cancer treatment, especially in neo and adjuvant therapy. ABC was mainly used as a combination therapy, and the correlation between influencing factors and ABC choice varied during different settings, indicating the preference and different perspectives of medication considered by medical oncologists regarding the use ABC in China.
KW - anthracycline
KW - breast cancer
KW - chemotherapy
KW - epidemiological study
KW - nation-wide
UR - https://www.scopus.com/pages/publications/85114012562
U2 - 10.1002/cam4.4215
DO - 10.1002/cam4.4215
M3 - Article
C2 - 34472719
AN - SCOPUS:85114012562
SN - 2045-7634
VL - 10
SP - 6744
EP - 6761
JO - Cancer Medicine
JF - Cancer Medicine
IS - 19
ER -
